<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02761811</url>
  </required_header>
  <id_info>
    <org_study_id>2015-01</org_study_id>
    <nct_id>NCT02761811</nct_id>
  </id_info>
  <brief_title>Sympathetic Mapping/ Ablation of Renal Nerves Trial</brief_title>
  <acronym>SMART</acronym>
  <official_title>A Prospective, Multicenter, Single Blind, Randomized and Controlled Trial of Renal Sympathetic Denervation Using SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator for the Treatment of Hypertension (SMART Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SyMap Medical (Suzhou), Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SyMap Medical (Suzhou), Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of targeted renal sympathetic denervation using SyMapCath
      I™ in patients with pharmacotherapy and uncontrolled hypertension for at least 6 months, then
      after standardized antihypertensive drug therapy (at least two drugs) for at least 28 days,
      office systolic blood pressure (BP) is still ≥ 150mmHg, ≤180mmHg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, single blind, randomized and controlled trial, in which
      patients are diagnosed with essential hypertension with at least six months of disease
      history and pharmacotherapy however their blood pressure still cannot be controlled. The
      patients will be informed, consent and get into a screening process. During the screening
      period patients will receive a standardized antihypertensive drug treatment for at least 28
      days and office BP is still ≥ 150mmHg, ≤180mmHg, and meet the inclusion and exclusion
      criteria. These patients will conduct renal artery angiography and be allocated to either
      renal sympathetic nerve denvervation group or renal artery angiography group by a randomizing
      system in a 1:1 ratio (212 patients, 106 paires). Patients with with office BP which is not
      achieved ideal level (&lt;140 mmHg) will titrate doses of classes of antihypertensive drugs
      according to a predefined standardized medication regimen until their office BP &lt;140 mmHg.
      Physicians who perform post-procedure patient management and physicians who perform renal
      denvervation procedures are blinded to each other.

      Patients will be followed at 7 days after the procedure or at discharge from hospital, 1
      month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months and 12months. Urine samples
      will be collected for drug tests to determine drug compliance of a patient.

      Data collecting/management/statistical analysis and laboratory tests will be performed by
      independent, qualified organizations. Independent DSMB/CEC are formed and responsible for
      assessments of protocol deviations and natures of SAEs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The control rates of office systolic blood pressure ( SBP&lt;140mmHg)</measure>
    <time_frame>6 month after the treatment</time_frame>
    <description>The control rates of office systolic blood pressure ( SBP&lt;140mmHg) at 6 month after the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The composite index of anti-hypertensive drugs</measure>
    <time_frame>6 months after the treatments</time_frame>
    <description>The composite index of anti-hypertensive drugs at 6 months after the treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in average 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative reduction in 24-hour ABPM reduction in systolic, diastolic and mean arterial blood pressure</measure>
    <time_frame>1 day (immediately after procedure)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in office BP</measure>
    <time_frame>1 month, 2 months, 3 months, 4 months, 5 months, 6 months, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in composite index of antihypertensive</measure>
    <time_frame>1 month, 2 months, 3 months, 4 months, 5 months, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of the renal interventional therapy procedure</measure>
    <time_frame>during the procedure</time_frame>
    <description>the renal denervation catheter can be engaged to the correct position in renal artery, successfully performed renal nerve ablation procedure and has no related complications such as renal arterial perforation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of clinical treatment</measure>
    <time_frame>7 days after the procedure or at the time the patient is discharged from hospital</time_frame>
    <description>based on succeed performance of renal interventional therapy procedure , there are no the procedure-related SAE, such as acute infection and renal dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>1 month, 3 months, 6 months, 9 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe renal dysfunction</measure>
    <time_frame>6 months</time_frame>
    <description>eGFR&lt;15mL/min/m2 or renal function replacement therapy needed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of renal artery stenosis assessed by CT angiography</measure>
    <time_frame>6 months</time_frame>
    <description>(stenosis &gt; 70% )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs, SAEs, and severe cardio-cerebrovascular events</measure>
    <time_frame>1 month, 3 months, 6 months, 9 months and 12months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal Sympathetic Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Masked Procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Percutaneous renal artery angiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator</intervention_name>
    <description>Radiofrequency ablation of renal arterial sympathetic nerves</description>
    <arm_group_label>Renal Sympathetic Denervation</arm_group_label>
    <arm_group_label>Masked Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and non-pregnant female subjects, 18≤age≤65

          2. Essential hypertension

          3. Office SBP ≥150mmHg and ≤180mmHg; and resting heart rate ≥70 bpm withouttaking beta
             blocker(Resting heart rate does not taken into account if beta blocker is not taken)

          4. Average 24-hour ABPM systolic blood pressure ≥135mmHg

          5. History of hypertension is longer than 6 months

          6. Patient with poor blood pressure control after 6 months of antihypertensive drug
             therapy, understands the purpose of this study, and is willing to participate and sign
             the Informed Consent; then the patient receives standard antihypertensive drug
             treatment (at least two drugs) for at least 28 days, drug compliance ≥80%, office BP
             ≥150 mmHg and ≤180 mmHg.

          7. Patient is compliant and willing to complete clinical follow-up.

        Exclusion Criteria:

        1. Renal artery anatomy is unqualified including：

        (1) diameter &lt;4mm or treatable length &lt;25mm; (2) Multiple renal arteries and the main renal
        artery supplies a fraction of the blood flow less than 75% (3) Renal artery stenosis &gt;50%
        or any renal artery aneurysms on either side (4) History of renal artery PTA, including
        balloon angioplasty and stenting 2. eGFR &lt;45mL/min/1.73m2 (MDRD formula) 3. Hospitalized
        within one year due to hypertensive crisis 4. Average 24-hour systolic blood pressure (SBP)
        &lt;135mmHg 5. Pulse pressure＞80mmHg 6. During running in period, using standardized
        antihypertensive drugs and other antihypertensive drugs 7. Participated other clinical
        trials including both drug and medical device studies within 3 months enrollment 8. Female
        with pregnant or lactating, or having plans for pregnancy within 1 year 9. Patient with
        sleep apnea who needs chronic oxygen-breathing or mechanical ventilation support (for
        example, tracheostomy) 10. Patients previously or currently suffering from following
        diseases:

          1. Essential pulmonary arterial hypertension

          2. Type I diabetes

          3. Severe cardiac valvular stenosis with contradictions to significantly reduce blood
             pressure

          4. History of myocardial infraction (MI), unstable angina, syncope or cerebrovascular
             accidents within half year.

          5. History of primary aldosteronism, pheochromocytoma, aorta stenosis, hyperthyroidism or
             hyperparathyreosis

          6. Any disease conditions interfering the measurement of blood pressure (for instance,
             severe peripheral artery diseases, abdominal artery aneurysm, hemorrhagic disorders
             such as thrombocytopenia, hemophilia and severe anemia)

          7. Plans to have surgery or cardiovascular interventions within following 6 months

          8. alcohol abuse or unknown drug dependence history

          9. Neuroticisms such as depression or anxiety disorders

         10. Non-compliant patients unable to finish the research per physician's requests

        11. Any contradictions to conduct renal artery stimulation and ablation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong HUO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie WANG, MD, PhD</last_name>
    <phone>+8613511604566</phone>
    <email>jay329329@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qichao ZHAI, BM</last_name>
    <phone>+8613146218768</phone>
    <email>qczhai@jetmed.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei MA, MD</last_name>
      <phone>+8613681050902</phone>
      <email>kmmawei@sina.com</email>
    </contact>
    <investigator>
      <last_name>Wei MA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weimin WANG, MD</last_name>
      <phone>+8601088326666</phone>
    </contact>
    <investigator>
      <last_name>Weimin WANG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guisong WANG, MD</last_name>
      <phone>+8613701070359</phone>
    </contact>
    <investigator>
      <last_name>Wei GAO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Afflicted Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuehui YIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yuehui YIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norman Bethune International Peace Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongmei WANG, MD</last_name>
      <phone>+86031187998210</phone>
    </contact>
    <investigator>
      <last_name>Dongmei WANG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei General Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050057</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyong QI, MD</last_name>
      <phone>+86031185989696</phone>
    </contact>
    <investigator>
      <last_name>Xiaoyong QI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong JIANG, MD</last_name>
      <phone>+8602788041911</phone>
    </contact>
    <investigator>
      <last_name>Hong JIANG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoliang Chen, MD, PhD</last_name>
      <phone>+8613605157029</phone>
      <email>chmengx@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Kan</last_name>
      <phone>+8615305140515</phone>
      <email>kanjingok@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minglong CHEN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Minglong CHEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bing YANG, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Afflicted to School of Medicine, Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben HE, MD</last_name>
      <phone>+8602158752345</phone>
    </contact>
    <investigator>
      <last_name>Ben HE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangfei WANG, MD</last_name>
    </contact>
    <investigator>
      <last_name>Junbo GE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaijun CUI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kaijun CUI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin First Center Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300192</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengzhi LU, MD</last_name>
      <phone>022-23626600</phone>
    </contact>
    <investigator>
      <last_name>Chengzhi LU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Our decision on whether to share the individual participant data depends on the opinions of the regulatory authorities in China, but so far the regulatory agencies have no clear instructions yet, so we cannot make a decision at present.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

